Phar­ma ad­ver­tis­ers’ cov­et­ed 50+ au­di­ence flocks to stream­ing TV, Roku analy­sis says

3 years ago
Pharma
Marketing

CRISPR hires William Blair an­a­lyst as new fi­nance chief; Tiny EU biotech rais­es $20M+

3 years ago
News Briefing

Bris­tol My­ers pass­es on two Ex­sci­en­tia on­col­o­gy can­di­dates, but biotech to move them in­to clin­ic next year

3 years ago
Deals
R&D

Ex­er­cise in a pill? That's the fo­cus of Cam­bri­an's new pipeline com­pa­ny

3 years ago
Financing
R&D

Cell­tri­on teams up with an­oth­er Ko­re­an bio­phar­ma in an­ti­body dis­cov­ery deal

3 years ago
Deals
Discovery

Amy­lyx's ALS drug sales beat Wall Street ex­pec­ta­tions in first full quar­ter

3 years ago
Pharma

Eli Lil­ly, UCB and oth­ers Switch in­to gear with $52M for new RNA biotech

3 years ago
Financing
Startups

No­vo-backed start­up touts a PhII win for atri­al fib­ril­la­tion pro­gram

3 years ago
R&D

VA to cov­er Ei­sai's new Alzheimer's drug af­ter de­clin­ing to cov­er Aduhelm

3 years ago
Pharma

Sun Phar­ma, Taro Phar­ma­ceu­ti­cal reach $75M set­tle­ment agree­ment in al­leged price fix­ing scheme

3 years ago
R&D
Law

Re­searchers ques­tion val­ue of Medicare Part D cov­er­age for obe­si­ty drugs

3 years ago
Pharma

PhRMA-backed al­liance says it wants to 'mod­ern­ize' the 340B pro­gram. Crit­ics say the changes will on­ly lim­it ac­cess

3 years ago
Pharma

GSK chief Em­ma Walm­s­ley sees pay raise amid 'land­mark' year

3 years ago
People
Pharma

Pfiz­er CEO points to IRA as a fac­tor that made Seagen an at­trac­tive tar­get

3 years ago
Pharma
Law

Al­con takes a new look at oph­thalmic phar­ma space and mar­ket­ing, post No­var­tis spin­out and raft of ac­qui­si­tions

3 years ago
Marketing

Mer­ck asks EMA to reeval­u­ate re­ject­ed Covid-19 an­tivi­ral

3 years ago
FDA+
Coronavirus

Im­munother­a­py biotech un­stealths with $13M; An­ti-in­fec­tion can­di­date for CF pass­es safe­ty tri­al

3 years ago
News Briefing

For­mer long­time an­a­lyst Ja­mi Ru­bin re­signs from EQRx's CFO role

3 years ago
People

FDA paus­es Mer­sana’s clin­i­cal tri­al af­ter pa­tient dies

3 years ago
FDA+

Cal­lid­i­tas plans to file for full ap­proval for rare kid­ney dis­ease drug fol­low­ing PhI­II da­ta

3 years ago
R&D
FDA+

Up­dat­ed: Carl Ic­ahn pro­pos­es three new Il­lu­mi­na board mem­bers in proxy fight

3 years ago
People
Startups

Up­dat­ed: Pfiz­er to buy Seagen for $43B, end­ing long-run­ning M&A saga for biotech

3 years ago
Deals
Pharma

Sanofi to pay $2.9B for Proven­tion Bio and its di­a­betes-de­lay­ing drug Tzield

3 years ago
Deals
Pharma

Up­dat­ed: Aca­dia wins first FDA ap­proval for Rett syn­drome drug

3 years ago
FDA+
First page Previous page 375376377378379380381 Next page Last page
A service from the Financial Times